Axis-Shield ups expenditure on point-of-care R&D (Research and Development)
This article was originally published in Clinica
Executive Summary
Anglo-Norwegian company Axis-Shield is stepping up its R&D expenditure on point-of-care in vitro testing, with an additional £6m ($9.4m) over two years, on top of normal R&D costs, earmarked for accelerating the development of a low-cost multi-analyte instrument aimed at the doctor's office. The increased expenditure will be recorded in the company's pre-tax loss for the second half, pushing back analysts' profit forecasts. Already in the first half of 2002, the company had increased its R&D expenditure by 28% to £4.2m.
You may also be interested in...
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics
CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.